Genevation

Genevation: Revolutionizing Cancer Therapy with Precision Oncology At Genevation, we are transforming the landscape of cancer therapy through innovation. Established in 2022 in London, United Kingdom, we are a pioneering pre-clinical stage biotechnology company dedicated to developing personalized cancer vaccines and mRNA-based therapeutics. We have developed personalized Cancer Vaccines in two-weeks time for our pre-clinical trials. Our approach combines cutting-edge technology, such as AI-driven neoantigen discovery and advanced cell-free manufacturing platforms, to accelerate the development of precision oncology solutions tailored to individual patients. In 2024, we expanded globally with the launch of a state-of-the-art subsidiary in San Diego, California, bolstering our R&D and manufacturing capabilities to bring ground breaking therapies closer to reality. Join us in our mission to redefine cancer treatment and create a future where precision medicine transforms lives. Follow us for updates on our journey toward a new era in oncology. #Biotechnology #CancerResearch #mRNA #PrecisionOncology #Innovation